New Paper Alert! Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal Cancer: A Real-World Analysis
ESMO - Eur. Oncology Guido Ghilardi boccaccina Martina Carullo Paolo Ciracì Alberto Puccini Sara Lonardi

Summary by Amalya Sargsyan…

Out on Cancer TreatmentReviews
Advancements in #ColorectalCancer treatment:
Review of ongoing trials using liquid biopsy to detect circulating tumor DNA🧬 which could revolutionize adjuvant therapy decisions

✅Ongoing trials explore ctDNA-guided strategies, from de-escalation…

New real world data about BRAF mutant mCRC. What are we doing after the targeted therapy? Università di Pisa GONO Foundation OncoDaily

Waiting for the liquid revolution: check out our review of ongoing trials to optimize the adjuvant therapy of CRC through ctDNA 🩸 OncoAlert GONO Foundation

🩸Liquid biopsy to guide adjuvant treatment (tx) choice in CRC
👉 doi.org/10.1016/j.ctrv…

Our review on ongoing trials investigating:
👉 tx intensification in ctDNA + pts
👉 tx de-escalation in ctDNA - pts
👉 post-adjuvant tx in ctDNA + pts

Chiara Cremolini Oncology Advance

Call for Abstracts! Showcase your research at #ESMOGI24 , 26-29 June, Munich, Germany, and online! Submit your abstract by 9 April 2024 to join leading experts in advancing GI oncology. Don't miss this opportunity to make an impact!

📣 Watch Lizzy Smyth, Juan Manuel O'Connor, Jeanne Tie, Chiara Cremolini, Angela Lamarca, Eric Van Cutsem, Ducreux Michel & Teresa Macarulla giving their reasons to attend the #ESMOGI24 . Early registration fees are available until ⏲️ 10 April!
🔗ow.ly/n31J50QOVBJ

Our Editor Spotlight this week is Chiara Cremolini, MD, PhD (Chiara Cremolini), Ass. Editor for GI tumors ESMO Open. Prof. Cremolini conducts clinical & translational research in colorectal and other GI tumors, with pivotal work in treatment intensification and biomarker discovery.

#ASCOGI24 | Dr. Cathy Eng: GALAXY primo studio a dimostrare che una variazione dinamica del ctDNA > al 50% a 6 mesi dalla chemioterapia adiuvante è associata a una migliore sopravvivenza libera da malattia'. #colonretto

tinyurl.com/mtu54fhv

#biopsialiquida Chiara Cremolini

The first piece of knowledge from PARERE trial by GONO Foundation
✅ > 200 pts candidate to antiEGFR rechallenge screened with #liquidbiopsy 🩸
⛔️38% RAS or BRAF mutations in ctDNA
🔢 30% RAS/BRAF wt cases with at least one potential mechanism of resistance
Paolo Ciracì

Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) nej.md/3M8Qw3k

#ESMO23 #oncology

#ESMO23 | mCRC: trattamento sequenziale REG e TAS, con o senza bevacizumab. Ne abbiamo parlato con Chiara Cremolini

Filippo Pietrantonio Università di Pisa Carmelo Pozzo ESMO - Eur. Oncology

tinyurl.com/3bx8xmy7

#ESMO23 | Chiara Cremolini: “The combination of sotorasib and panitumumab will likely become a new standard of care for KRAS G12C mutant #mCRC patients”.

#CodeBreak300

Filippo Pietrantonio ESMO - Eur. Oncology Sharlene Gill, MD, MPH, MBA, FASCO Carmelo Pozzo Istituto Tumori Università di Pisa

AI-powered TILs analysis by Lunit Scope in the AtezoTRIBE study.
Poster session today at ESMO - Eur. Oncology 🎗️571P
So grateful to Chiara Cremolini e carlottanto ❤️.
Sincere thanks to my collegues at Lunit Inc. for this and future collaborations.

Stay tuned.⚡

#ESMO23 : Can we avoid preoperative (chemo)radio in locally advanced #RectalCancer ? Controversy session, Chiara Cremolini: PROSPECT results must be interpreted vs detailed disease features. #ESMODailyReporter #CRCSM #GICancer
📌ow.ly/oSZo50PZFAY

Can’t wait to meet colleagues and friends at #ESMO23 - Exciting news in the Lower GI track… targeted agents ready for prime time, immunotherapy and liquid biopsies on the horizon ESMO - Eur. Oncology

Martina Carullo, AIOM Giovani, è una delle vincitrici del Premio per il migliore abstract “Oncologia su misura”. In questo video ci parla del suo lavoro:
youtu.be/7Wpf9I56yns

#aiomgiovani #aiomtv

Marco Germani (AOUP / Azienda ospedaliero-universitaria pisana) presents on the predictive impact of RNF43 mutation in pMMR/MSS BRAFV600E mCRC patients treated with targeted therapy or chemotherapy.

ESMO - Eur. Oncology #WCGIC2023 #GIsm #CRCsm

ERASE-CRC trial
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Pts

Gruppo Oncologico del Nord-Ovest
Chiara Cremolini
#MRDtrial
Resected stage III & high-risk stage II colon cancer pts w/ positive ct- DNA
clinicaltrials.gov/study/NCT05062…